News

Results represent the first positive Phase III clinical trial in a dry eye chamber with a symptom as the primary endpoint.

In the fourth and final part of this video interview, Vincent Keunen, founder & CEO of Andaman7 looks forward and highlights some potential advancements with the use of AI.

Induction therapy comprised of Sarclisa (isatuximab-irfc; Sanofi) plus lenalidomide, bortezomib, and dexamethasone significantly improved progression-free survival from first randomization in transplant-eligible patients with newly diagnosed multiple myeloma.

Overcoming saturation in the cell therapy landscape.

In part 3 of this video interview, Vincent Keunen, founder & CEO of Andaman7 shares his own experience as a patient when it comes to using digital applications.

Patients in the Keytruda (pembrolizumab)-vibostolimab combo plus chemotherapy arm experienced a higher rate of adverse events compared to those in the control arm.

Results show nipocalimab could address the high unmet need of patients with severe hemolytic disease of the fetus and newborn, which is a life-threatening and rare condition with no other therapies currently in clinical development.

In part 2 of this video interview, Vincent Keunen, founder & CEO of Andaman7 highlights how technology vendors should be keeping the patient in mind when building solutions.

In a presentation at the 2024 International Association for the Study of Pain World Congress, Concentric Analgesics shared positive Phase II data for its lead candidate.

Study shows efficacy of olanzapine in improving complete response rates and chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens comprised of oxaliplatin, carboplatin, or irinotecan.

In part 1 of this video interview, Vincent Keunen, founder & CEO of Andaman7 discusses how service providers and sponsors can make the lives of patients contributing to research easier.

Phase III study of Bayer’s non-steroidal, selective mineralocorticoid receptor antagonist met its primary endpoint.

Tremfya dosing at an interval of every 16 weeks was noninferior to the standard every eight weeks dosing interval for maintenance of psoriasis disease control.

In the fifth and final part of this video interview, Rama Kondru, PhD, CEO of Veridix AI looks forward to what the LLM landscape in clinical trials could look like in five years.

Phase III study of tirzepatide in adults with heart failure with preserved ejection fraction and obesity met all primary endpoints.

Multiple observational studies have shown that patients with cancer and a higher body mass index who were administered chemotherapy experienced improved survival compared to patients with normal body weight.

In part 4 of this video interview, Rama Kondru, PhD, CEO of Veridix AI discusses best practices for choosing the right artificial intelligence solutions.

Phase IV study finds antihypertensive therapy guided by ambulatory blood pressure monitoring improves target organ damage in patients with masked hypertension.

Giving sites and sponsors an effective tool for principled negotiations.

In part 3 of this video interview, Rama Kondru, PhD, CEO of Veridix AI touches on how large language models can leverage unstructured data.

The trial demonstrated clinically meaningful improvements in overall response rate and duration of response in its patient population.

Phase III DREAMM 7 trial data show median progression-free survival of 36.6 months with Blenrep (belantamab mafodotin), bortezomib, and dexamethasone compared to 13.4 months with Darzalex (daratumumab), bortezomib, and dexamethasone.

In part 2 of this video interview, Rama Kondru, PhD, CEO of Veridix AI highlights areas that large language models can be used in clinical trials including patient recruitment and retention.

According to the trial data, PGN-EDO51 is outperforming previously studied oligonucleotide therapies.

In part 1 of this video interview, Rama Kondru, PhD, CEO of Veridix AI discusses challenges with adoption and the potential uses of large language models in clinical trials.

Randomized trial finds once daily oral semaglutide 50 mg lowered energy intake, appetite, and food cravings, with improved control of eating and clinically meaningful reductions in body weight after 20 weeks.

AstraZeneca’s CALQUENCE (acalabrutinib) in combination with venetoclax, with or without obinutuzumab achieved the significant and clinically meaningful improvement in the AMPLIFY Phase III trial.

Vincent Keunen, founder and CEO of Andaman7 shares his thoughts on how industry can achieve true patient centricity through emerging platforms and digital tools.

Phase IIb trial indicates liraglutide (Novo Nordisk) may reduce cognitive decline associated with Alzheimer disease by protecting against shrinkage in areas of the brain controlling memory, learning, language, and decision-making.

The CETP inhibitor lowered low-density lipoprotein cholesterol by 36.3% at day 84 and 41.5% at day 365 compared to placebo.